Deals channel feed – Endpoints News

Deals channel feed

Buzz: This little biotech has so much going against it, somebody is going to want to buy it. Right?

7 years ago

As it digests Shire, Takeda plans to shed $10B in non-core assets to relieve debt burden

7 years ago

With mega merger season in full swing, Takeda officially swallows Shire

7 years ago

#JPM19 starts with Eli Lilly's $8B buyout of Loxo Oncology — so who's next?

7 years ago

Celgene sweetened the pot for exec team ahead of Bristol-Myers merger announcement

7 years ago

Bristol-Myers inks a $74B deal to buy out Celgene, expects $15B a year from late-stage pipeline

7 years ago

Can Novartis slim down CAR-T manufacturing timelines with its latest acquisition attempt?

7 years ago

Novo Nordisk grabs a $486M buyout option on an anti-apoC3 antibody for its cardio R&D group

7 years ago

Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout

7 years ago

Mereo reverse merges with a flailing OncoMed and preps for a back flip onto Nasdaq

7 years ago

A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames

7 years ago

GSK bags Tesaro for $5B as it leaps back into commercial oncology and beefs up cancer drug pipeline

7 years ago

Giant Roche wades into the preclinical NLRP3 pool, bagging Jecure for their anti-inflammatory team at Genentech

7 years ago

Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains

7 years ago

Immunotherapy developer Enlivex uses Bioblast shell to reverse merge its way onto Nasdaq

7 years ago

Tesaro stock soars on another report the PARP player is exploring a sale

7 years ago

Introducing SVB Leerink: SVB bags Leerink Partners for $280M as a major player spreads its wings during a life sciences boom

7 years ago

With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan

7 years ago

Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?

7 years ago

From zero to hero: Endocyte’s little deal a year ago spurred a comeback capped by $2.1B Novartis buyout

7 years ago

Seeking cash to fund PhIII for once-failed drug, Adynxx rides Alliqua's shell to Nasdaq

7 years ago

Blackstone bags Clarus, staking out a growing PhIII niche for itself in a rapidly changing biopharma industry

7 years ago

Roche scoops up a Treg player for the I/O team, plucking 1 drug and spinning off a 2nd into a new biotech

7 years ago

Alexion gambles on an early-stage drug for rare diseases, bagging Apple Tree-backed Syntimmune in $1.2B buyout

7 years ago

First page Previous page 105 106 107108109 110 111 Next page Last page